Direct interaction of post-synaptic density-95/Dlg/ZO-1 domain-containing synaptic molecule Shank3 with GluR1 alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor
Oral GLP-1: A Game-Changer for Patients and Payers Since the GLP-1 market emerged, patients and investors have wondered about the feasibility of an oral solution
Serum levels of soluble secreted alpha-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis
The type-2 isozyme is sensitive to finasteride, a 5 -reductase-2 inhibitor, while the type-1 has a lower sensitivity
While these effects are often temporary, they can be significant enough to lead patients to reduce doses, pause treatment, or stop altogether
Men with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use semaglutide